AHA: Pelacarsen cuts lipoprotein(a) levels but does not lower risk for major adverse cardiovascular events
For adults with preexisting cardiovascular disease, pelacarsen, an antisense oligonucleotide administered monthly, lowers lipoprotein(a) levels but does not reduce the occurrence of major adverse cardiovascular events, according to a study published online Nov. 7 in the New England Journal of Medicine to coincide with the American Heart Association Scientific Sessions 2026, held from Nov. 6 to 9…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
7 simple self-care habits that may ease anxiety and depression
United Kingdom
-
Mediterranean diet can help clear fat from the pancreas and improve blood-sugar control
United Kingdom
-
Inhaled living medicine reduces drug-resistant lung biofilms in the lungs of pigs
United Kingdom
-
Sleep-like brain waves during wakefulness linked to Parkinson's symptoms
United Kingdom
-
Simple outpatient scoring system cuts deaths among malnourished children
United Kingdom
-
How to test whether brain organoids possess consciousness
United Kingdom
-
Stress worsens quality of life in adults with multiple illnesses
United Kingdom
-
European long-term care models offer valuable lessons for the U.S.
United Kingdom